Suchergebnisse - "Rosell, Rafael"

PubPharm (837)

1

Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions

enthalten in: Expert opinion on investigational drugs | 2024

von Rosell, R. | Pedraz-Valdunciel, C. | Jain, A. | +2

2

PD-1-induced encephalopathy : a report of 2 cases on neurological toxicities with immune checkpoint inhibitors

enthalten in: Translational cancer research | 2024

von Chen, X. | Ye, M. | Ai, R. | +15

3

Chemotherapy in EGFR-mutated NSCLC : optimizing combinations with TKIs and amivantamab

enthalten in: Nature reviews. Clinical oncology | 2024

von Rosell, R. | González-Cao, M.

4

KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)

enthalten in: Critical reviews in oncology/hematology | 2024

von Rosell, R. | Codony-Servat, J. | González, J. | +8

5

Converging and evolving immuno-genomic routes toward immune escape in breast cancer

enthalten in: Nature communications | 2024

von Blanco-Heredia, J. | Souza, C. | Trincado, J. | +20

6

Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer : the Phase 2 randomized PIPSeN trial

enthalten in: British journal of cancer | 2024

von Postel-Vinay, S. | Coves, J. | Texier, M. | +17

7

Pangaea Oncology, Dexeus University Hospital : bridging preclinical and clinical research

enthalten in: Molecular cancer | 2024

von González-Cao, M. | Pedraz, C. | Molina-Vila, M. | +1

8

Unveiling Novel ERCC1-XPF Complex Inhibitors : Bridging the Gap from In Silico Exploration to Experimental Design

enthalten in: International journal of molecular sciences | 2024

von Manguinhas, R. | Serra, P. | Soares, R. | +4

9

Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Lara-Mejía, L. | Cardona, A. | Mas, L. | +12

10

Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways

enthalten in: Translational oncology | 2024

von García-Roman, S. | Garzón-Ibáñez, M. | Bertrán-Alamillo, J. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[84]